ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. BDRX, ABVC, PLUR, GRCE, MRNS, MAAQ, ALLK, SXTC, INKT, and RANIShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Biodexa Pharmaceuticals (BDRX), ABVC BioPharma (ABVC), Pluri (PLUR), Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), China SXT Pharmaceuticals (SXTC), MiNK Therapeutics (INKT), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors Biodexa Pharmaceuticals ABVC BioPharma Pluri Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos China SXT Pharmaceuticals MiNK Therapeutics Rani Therapeutics ObsEva (NASDAQ:OBSV) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Which has stronger earnings and valuation, OBSV or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than ObsEva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEva$20.11M0.00-$58.38M-$0.92N/ABiodexa Pharmaceuticals$470K67.64-$7.32MN/AN/A Is OBSV or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Biodexa Pharmaceuticals N/A N/A N/A Does the media prefer OBSV or BDRX? In the previous week, Biodexa Pharmaceuticals had 10 more articles in the media than ObsEva. MarketBeat recorded 10 mentions for Biodexa Pharmaceuticals and 0 mentions for ObsEva. Biodexa Pharmaceuticals' average media sentiment score of 0.19 beat ObsEva's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment ObsEva Neutral Biodexa Pharmaceuticals Neutral Which has more risk and volatility, OBSV or BDRX? ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Do insiders and institutionals believe in OBSV or BDRX? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryBiodexa Pharmaceuticals beats ObsEva on 6 of the 9 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$825.11M$5.48B$8.87BDividend YieldN/A4.84%5.35%4.15%P/E Ratio-0.111.3226.2119.66Price / SalesN/A222.96386.95105.10Price / CashN/A23.4436.4056.81Price / BookN/A6.117.905.44Net Income-$58.38M-$26.95M$3.16B$249.37M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150BDRXBiodexa Pharmaceuticals0.5211 of 5 stars$0.92+6.2%N/AN/A$31.67M$470K0.0020News CoverageGap DownABVCABVC BioPharma0.3296 of 5 stars$1.96+6.5%N/A+251.5%$31.25M$510K-15.0830News CoveragePLURPluri2.9845 of 5 stars$4.39+10.9%$12.00+173.3%-5.4%$31.03M$330K-0.79150Gap UpHigh Trading VolumeGRCEGrace Therapeutics2.3616 of 5 stars$2.93-2.3%$12.00+309.6%N/A$30.42MN/A-2.53N/AEarnings ReportHigh Trading VolumeMRNSMarinus Pharmaceuticals2.2557 of 5 stars$0.55-0.2%$3.92+613.3%-55.4%$30.32M$30.99M-0.22110MAAQMana Capital AcquisitionN/A$3.71-4.6%N/A+502.2%$30.14MN/A0.001ALLKAllakos2.7882 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190SXTCChina SXT Pharmaceuticals0.4556 of 5 stars$1.84flatN/A-80.7%$29.12M$1.93M0.0090INKTMiNK Therapeutics3.3719 of 5 stars$7.48+3.0%$37.50+401.3%-24.9%$28.94MN/A-2.9730Positive NewsRANIRani Therapeutics2.2086 of 5 stars$0.49-2.1%$7.33+1,396.6%-86.0%$28.77M$1.03M-0.49110Positive News Related Companies and Tools Related Companies Biodexa Pharmaceuticals Alternatives ABVC BioPharma Alternatives Pluri Alternatives Grace Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Allakos Alternatives China SXT Pharmaceuticals Alternatives MiNK Therapeutics Alternatives Rani Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBSV Stock Free OBSV Stock Alerts